Uppsala, January 4, 2023. The pharmaceutical company Dicot announces the contracting of reputable Clinical Trial Consultants AB (CTC) for conducting clinical phase 1 studies intended to start in mid-2023. The studies will take place at the contracted company's research clinic in Uppsala.
Dicot is developing a new potency drug with the aim to treat erectile dysfunction and premature ejaculation better than existing drugs. The company has earlier announced its intention to start clinical studies with the drug candidate LIB-01 in mid-2023.
As an important part of the preparations for starting clinical trials, Dicot has finalized the procurement process and selects CTC to conduct the phase 1 studies. CTC is a reputable CRO with a track record of over 400 completed studies for both small and large international pharmaceutical companies. CTC has five state-of-the-art clinical research units in Uppsala, Stockholm and Linköping. Dicot's phase 1 studies will take place at the clinical unit in Uppsala.
"CTC came out as the strongest candidate in our procurement process, in competition with several international companies. I'm convinced this will be a good collaboration built on high-level competence and great commitment from both parties. Our joint work starts already now in January," says Elin Trampe, CEO at Dicot.
"We are very excited about the opportunity to collaborate with a local innovative pharmaceutical company like Dicot, and together with them take their candidate LIB-01 into clinical trials for the first time", comments Anders Millerhovf, CEO at CTC.
For further information, please contact:
Elin Trampe, CEO
Tel: +46 739 80 14 08
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 60 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a studies and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.
Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit www.dicot.se.